NCT06569355

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight/Obese Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Vincentage Pharma Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo tablets for 16 weeks and will need to take tablets each morning. Participants will have 7 clinic visits and a final follow-up visit approximately 14 days after the last study intervention administration.

Detailed description

Not provided

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	VCT220	A small molecule GLP-1R agonist tablet, orally administration, once daily
DRUG	Placebo	Placebo tablet

Timeline

• Start date: 2023-12-27
• Primary completion: 2024-07-13
• Completion: 2024-08-01
• First posted: 2024-08-26
• Last updated: 2025-07-01

Locations

1 site across 1 country: China